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INTRODUCTION: The prevalence of sarcopenia varies exten-
sively depending on the definitions and studied popula-
tions. The aim of this study was to assess the prevalence of 
sarcopenia in a Danish geriatric out-patient population us-
ing criteria from the European Working Group on Sarco-
penia (EWGSOP).
METHODS: Patients referred to a geriatric outpatient-clinic 
were included. Using the EWGSOP´s recommendations, Ap-
pendicular skeletal muscle mass (ASM), hand-grip strength 
(HGS) and gait speed (ten-meter walk (GS)) were assessed. 
Skeletal muscle mass index (SMI) was calculated by ASM/
height2 (kg/m2), and patients were classified with: no sarco-
penia (normal SMI), pre-sarcopenia (reduced SMI, normal 
HGS and GS), sarcopenia (reduced SMI and reduced HGS or 
GS) or severe sarcopenia (reduced SMI, HGS and GS). 
RESULTS: A total of 189 patients were screened, 80 were in-
cluded. In all, 12 (15%) had severe sarcopenia, nine (11%) 
sarcopenia, eight (10%) pre-sarcopenia and 51 (64%) no sar-
copenia. Mean age was significantly higher in the SARC- 
group (sarcopenia and severe sarcopenia) than in the NO-
SARC-group (pre-sarcopenia and no sarcopenia) (p = 0.009), 
and BMI was significantly lower in the SARC-group (p < 
0.0001). No difference was found in gender distribution (p = 
0.729).
CONCLUSIONS: 26% of patients in a geriatric outpatient 
population had sarcopenia, which highlights that this is a 
common condition. Standard assessments can identify func-
tional limitations, but not sarcopenia. The EWGSOP’s re-
commendations are feasible, and we suggest that they 
should form part of the standard clinical comprehensive 
geriatric assessment. 
FUNDING: none.
TRIAL REGISTRATION: not relevant.
Sarcopenia is a multifactorial geriatric syndrome that is 
characterised by a progressive loss of skeletal muscle 
mass and associated with a high risk of physical disabil-
ity, poor quality of life and increased mortality [1, 2]. 
Rosenberg introduced the concept of sarcopenia in 
1988, and he stated that loss of lean body mass was the 
most significant age-related physical decline [3]. The 
first to propose a method for identifying sarcopenia, 
based on muscle mass, was Baumgartner and colleagues 
in the 1990s, using dual energy X-ray absorptiometry 
(DXA) [4]. Based on the criteria suggested by Baum-
gartner, the prevalence of sarcopenia was found to be 
13-24% among older people > 70 years, and up to 50% 
in older people > 80 years, depending on the population 
studied [4-6]. These studies are from Northern America 
and Italy.
However, accumulating data have demonstrated 
that muscle mass may not always be linearly related to 
muscle function [7, 8]. Moreover, functional parameters 
such as gait speed and hand-grip strength are strong 
predictors of disability and survival [9]. Consequently, 
the original definition of sarcopenia as purely a loss of 
muscle mass has evolved into one that includes a loss of 
both muscle mass and muscle function [10, 11]. The first 
steps towards a practical clinical definition and consen-
sus diagnostic criteria for age-related sarcopenia com-
bining muscle mass with muscle function and/or muscle 
strength were taken in 2009 by the International 
Working Group on Sarcopenia (IWGS) and in 2010 by the 
European Working Group on Sarcopenia (EWGSOP) [10, 
11]. The latter group suggests that the comprehensive 
geriatric assessment (CGA) (a multidimensional interdis-
ciplinary diagnostic process focused on determining a 
frail older person’s medical, psychological and functional 
capability in order to develop a coordinated and integ-
rated plan for treatment and long-term follow-up) 
should include assessment of sarcopenia in terms of 
measurements of muscle mass, hand-grip strength and 
gait speed [11]. 
Based on outcomes, sarcopenia is categorised as:  
1) pre-sarcopenia (low muscle mass, normal function 
and normal strength), 2) sarcopenia (low muscle mass 
and either low strength or low function), or 3) severe 
sarcopenia (low muscle mass and low strength and low 
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function) [11]. Despite these initiatives and the severe 
consequences of sarcopenia, a widespread clinical use of 
the concept is still lacking, and the European algorithm 
for assessing sarcopenia has not yet been fully imple-
mented in geriatric clinical practice in Denmark.
The objective of this cross-sectional study was 
therefore to assess the prevalence of sarcopenia in a 
Danish geriatric out-patient population based on the 
recommendations from the EWGSOP. In addition, the 
purpose was to describe the association between sarco-
penia and age, gender, BMI and prevalence of chronic 
diseases in the study population. Furthermore, we 
 wanted to evaluate if the sarcopenia assessment based 
on these recommendations is superior to currently used 
geriatric tests for muscle function and muscle strength 
for identification of patients with sarcopenia.
mEthOds
The study population consisted solely of patients re-
cruited from a geriatric out-patient clinic (the Geriatric 
Section, Medical Department, Rigshospitalet – Glostrup) 
who were consecutively assessed for inclusion in the 
study from June 2014 through May 2015. Patients were 
referred to the geriatric out-patient clinic for fall assess-
ment, geriatric assessment or follow-up after admission 
from wards at Rigshospitalet – Glostrup, other hospitals, 
or general practitioners. There was no recruitment from 
the emergency department. All patients provided their 
written, informed consent to participate in the extended 
assessment programme. The local ethical committee ap-
proved the study (H-3-2013-124).
The exclusion criteria were: age < 65 years, severe 
communicative problems, moderate-severe dementia 
and no independent walking. Figure 1 presents a flow 
chart of the inclusion process. Data on the included pa-
tients were collected, including demographics, nutri-
tional status (BMI) and comorbidity. 
dual energy X-ray absorptiometry
Appendicular skeletal muscle mass (ASM) was defined as 
the sum of soft lean tissue masses for arms and legs, as-
suming that all non-fat and none-bone are skeletal mus-
cle. ASM was determined by DXA, using a Lunar iDXA 
scanner (GE Medical Systems, Madison, WI, USA) at the 
Department of Clinical Physiology, Nuclear Medicine & 
PET, Rigshospitalet – Glostrup. The Skeletal Muscle Mass 
Index (SMI) was defined by ASM/height2 (kg/m2) with 
cut-off values similar to those reported by Newmann 
and colleagues (men: < 7.23 kg/m2, women: < 5.67 kg/
m2) [12].
hand-grip strength
Muscle strength was determined by hand-grip strength 
with a hand grip dynamometer (DHD-1 Digital Hand Dy-
namometer, Saehan 2012) ad modum the Southampton 
Protocol [13]. In brief, the patient was in a seated pos-
ition with the arm supported by a horizontal surface. 
The best of three trials was used for the dominating 
hand. The cut-off values suggested by Lauretani and col-
leagues were used (men: < 30 kg, women: < 20 kg) [14].
gait speed
Muscle function was measured by testing gait speed us-
ing the ten-meter walk test with a cut-off value of < 0.8 
m/sec. for both men and women [15].
Sarcopenia was classified in accordance with the 
EWGSOP criteria [11]:
• No sarcopenia: normal muscle mass
• Pre-sarcopenia: low muscle mass but normal 
muscle strength and normal muscle function 
• Sarcopenia: low muscle mass and either low muscle 
strength or low muscle function 
• Severe sarcopenia: low muscle mass, low muscle 
strength and low muscle function.
FigURE 1
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In addition, the patients were tested with chair stand 
test [16] and Timed Up and Go test [17] as a part of 
standard CGA in the geriatric outpatient clinic. Cut-off 
values: Timed Up and Go: > 12 sec. and chair stand in ac-
cordance with the patient’s age and gender [16]. The 
physical tests were performed by trained physiothera-
pists at the outpatient clinic Geriatric Section, Medical 
Department, Rigshospitalet – Glostrup.
statistics
SAS Enterprise Guide 7.1 was used for the statistical 
analyses. Unless otherwise stated, continual variables 
are presented with mean ± standard deviation and cat-
egorical variables are presented with numbers and per-
centage in the presentation of group characteristics. Un-
paired t-test, chi-squared test and Fisher’s exact test 
were used as appropriate in the comparison of the 
groups. To overcome confounding differences between 
groups, we performed a multivariate logistic regression 
analysis with sarcopenia status as the dependent vari-
able and age > 80 years, low BMI (BMI ≤ 20.5 kg/m2) and 
gender as the covariates. Due to limited sample size, the 
sarcopenia groups were pooled into two: the no sarco-
penia group (no sarcopenia + pre-sarcopenia) and the 
sarcopenia group (sarcopenia + severe sarcopenia).
Trial registration: not relevant.
REsUlts
Participants
A total of 189 patients were screened for inclusion and 
18 of these were excluded according to the exclusion 
criteria. In all, 82 patients signed an informed consent 
form and were included, and 80 patients completed the 
full study (Figure 1).
Demographic baseline characteristics, functional 
ability and results of muscle mass measurements are 
presented in table 1. The mean age in the study popula-
tion was 79 years (65-94 years). Most of the participants 
were women (65%), and the majority of the patients 
were referred for fall assessment (78%). A low BMI was 
found in 20% of the patients > 80 years and in 9% among 
patients < 80 years.
Prevalence of sarcopenia based on the  
European Working group on sarcopenia criteria
When classifying the patients in accordance with the cri-
teria from the EWGSOP, 12 (15%) were found to have 
severe sarcopenia, nine (11%) sarcopenia, eight (10%) 
pre-sarcopenia and 51 (64%) no sarcopenia. In total, 21 
(26%) had clinical sarcopenia, i.e. sarcopenia and severe 
sarcopenia, whereas 59 (74%) did not have sarcopenia. 
The classification of sarcopenia in comparison with pa-
tient characteristics is shown in table 2.
The mean age was significantly higher in the group 
with sarcopenia and severe sarcopenia than in the group 
without sarcopenia (p = 0.009). No difference was found 
in gender distribution (p = 0.729) (Table 2). Contrary to 
our expectations, the prevalence of chronic diseases 
such as diabetes and polyneuropathy was higher in the 
group without sarcopenia than in the group that had 
sarcopenia (Table 2). 
A multivariate logistic regression analysis was per-
formed with clinical sarcopenia (sarcopenia and severe 
sarcopenia) as the dependent variable and the following 
covariates in the model: age > 80 years, low BMI and fe-
tablE 1
Demographic characteristics and data on muscle mass and functional ability.
all Women men
(n = 80) (n = 52) (n = 28)
Age, mean ± SD (range), yrs 79 ± 6.6 (65-94) 80 ± 6.9 (65-92) 79 ± 6.2 (68-94)
Referral type, n (%) 
Fall assessment 62 (78) 41 (79) 21 (75)
Geriatric assessment 18 (23) 11 (21)   7 (25)
Follow-up after admission, n (%) 13 (16)   7 (14)   6 (21)
Comorbidity, n (%)
Diabetes 19 (24) 12 (23)   7 (25)
Neurological disease   5(6)   4 (8)   1 (4)
Uraemia 10 (13)   7 (14)   3 (11)
Heart disease   7 (9)   3 (6)   4 (14)
Parkinson’s disease   2 (3)   2 (4)   0
Polyneuropathy 28 (35) 15 (29) 13 (46)
Stroke 25 (31) 15 (29) 10 (36)
BMI
Low BMIa, n (%) 11 (14)   6 (12)   5 (18)
BMI, mean ± SD (range), kg/m2 26.2 ± 5.1 (15-42) 26.3 ± 5.3 (15-40) 26 ± 4.8 (18-42)
TUG
Pathological TUG, n (%) 34 (47) 25 (48) 9 (32)
TUG, mean ± SD (range), sec. 15.4 ± 11.4 (6-90) 16.5 ± 13.1 (9-90) 13.3 ± 7 (6-32)
Pathological CS, n (%) 45 (62) 28 (54) 17 (61)
GS
Pathological GS, n (%) 23 (29) 15 (29) 8 (29)
GS, mean ± SD (range), m/sec. 1,1 (0,1-3) (0,5) 1,0 (0,1-2) (0,4) 1,2 (0,2-3) (0,5)
HGS
Pathological HGS, n (%) 42 (53) 29 (56) 13 (46)
HGS, mean ± SD (range), kg 23.8 ± 7.9 (9-46) 19.6 ± 4.7 (9-30) 31.5 ± 6.8 (16-46)
SMI
Pathological SMI, n (%) 29 (36) 17 (33) 12 (43)
SMI, mean ± SD (range), kg/m2 6.7 ± 1.2 (4-12) 6.7 ± 1.3 (4-12) 6.9 ± 1.1 (5-9)
CS = chair stand test; GS = gait speed test; HGS = hand-grip strength test; SD = standard deviation; SMI = 
skeletal muscle mass index; TUG = Timed Up and Go test.
a) ≤ 20.5 kg/m2.
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male gender. The results showed that in this study, high 
age and poor nutritional status were associated with a 
higher risk of sarcopenia, whereas female gender was 
not (table 3). 
muscle strength and functional performance
Low muscle strength as measured by hand-grip strength 
was found in 53% and according to the chair stand test 
in 62%. Low muscle function measured by gait speed 
and Timed Up and Go was present in 29% and 47% pa-
tients, respectively. A pathological muscle mass was 
found in 36% of the patients. The number of patients 
with a low muscle strength as measured by the chair 
stand test was 14 (67%) in the sarcopenia group and 31 
(53%) in the group without sarcopenia; whereas meas-
ured by hand-grip strength, it was 20 (95 %) in the sarco-
penia group versus 22 (37%) in the group without sarco-
penia.
Low muscle function measured by the Timed Up 
and Go test was found in 13 (62%) in the group with sar-
copenia and in 21 (36%) in the group without sarcope-
nia; and by gait speed in 13 (62%) in the sarcopenia 
group versus ten (17%) in the group without sarcopenia. 
The results of the chair stand and Timed Up and Go are 
shown in Table 2.
The negative predictive value was 89% for the chair 
stand test and 90% for Timed Up and Go, indicating that 
a patient with a normal test result has a very low prob-
ability of having sarcopenia (Table 3). The low positive 
predictive values for the chair stand test (31%) and the 
Timed Up and Go test (38%) indicate that these tests 
cannot be used as predictive assessment tools for sarco-
penia (Table 3).
discUssiOn
The aim of the present study was to assess the preva-
lence of clinical sarcopenia in a Danish geriatric out- 
patient population based on the EWGSOP recommen-
dations. To the best of the authors’ knowledge, this is 
the first study to do so.
In this study population, the prevalence of clinical 
sarcopenia (sarcopenia + severe sarcopenia) was 26%, 
which is in line with data from similar populations [6, 10, 
18, 19]. Comparable studies have found sarcopenia to 
fall in the 4-29% range [10]. A recent study from The 
Netherlands demonstrated prevalence rates for sarco-
penia in a geriatric out-patient population of 17-22% 
[18].
One of the strengths of this study was that, once in-
cluded, 98% of the patients completed the assessment 
programme; yet, the participation rate was only 48%.  
A plausible explanation could be that the frailest pa-
tients were the ones who declined to participate, there-
by making the results less representative for the overall 
population in the geriatric outpatient clinic. This com-
bined with the small study size may restrict the general-
isability of the results.
Furthermore, this study underlines the difficulty of 
distinguishing if functional limitations are due to sarco-
penia or other conditions. A relatively high percentage 
of the tested patients had functional limitations in terms 
of low muscle strength and low muscle function without 
low muscle mass. As most of the patients were referred 
for fall assessment, functional disability due to, e.g., bal-
ance disturbances may interfere with functional disabi l-
ity due to low muscle function. Fear of falling and lack of 
motivation may be other possible confounding ele-
ments. This may have entailed an overestimation of the 
prevalence of clinical sarcopenia when using the 
EWGSOP definition in the present population. Another 
aspect is the American reference material on which the 
clinical diagnosis of sarcopenia is based when the 
tablE 2
Sarcopenia classification in comparison with patient characteristics.
nOsaRc-group saRc-group
(n = 59) (n = 21) p-value
Age, mean ± SD, yrs 78.1 ± 6.4 82.5 ± 6.3 0.009c
Age ≥ 80 yrs, n/N (%) 20/59 (33.9) 15/21 (71.4) 0.003d
Gender, n/N (%) 0.729d
Male 20/59 (33.9)   8/21 (38.1)
Female 39/59 (66.1) 13/21 (61.9)
BMI
BMI, mean ± SD, kg/m2 27.8 ± 4.7 21.7 ± 3.1 < 0.0001c
Low BMIa, n (%) 2/59 (3.4) 9/21 (42.9) < 0.0001e
Chronic diseases, n/N (%)
Diabetes 19/59 (32.2) 0/21 0.002e
Neurological disease    5/59 (8.5) 0/21 0.318e
Uraemia    8/59 (13.6) 2/21 (9.5) 1.000e
Heart disease    4/59 (6.8) 3/21 (14.3) 0.371e
Parkinson    1/59 (1.7) 1/21 (4.8) 0.459e
Polyneuropathy 25/59 (42.4) 3/21 (14.3) 0.021d
Stroke 20/59 (33.9) 5/21 (23.8) 0.392d
Pathological test values, n/N (%)
TUGb 21/56 (38) 13/17 (76) 0.0048d
CSb 31/56 (55) 14/17 (82) 0.045d
GS 10/59 (17) 13/21 (62) < 0.0001d
HGS 22/59 (37) 20/21 (95) < 0.0001d
CS = chair stand test; GS = gait speed test; HGS = hand-grip strength test; NOSARC = no sarcopenia +  
pre-sarcopenia; SARC = sarcopenia + severe sarcopenia; SD = standard deviation; TUG = Timed Up and 
Go test.
a) ≤ 20.5 kg/m2.
b) 7 missing values for TUG and CS.
c) Unpaired t-test.
d) Chi-squared test.
e)  Fisher’s exact test.
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EWGSOP recommendations are used. As far as we know, 
a European reference material for muscle mass is still 
lacking.
In this study, high age and poor nutritional status 
were found to be associated with sarcopenia, which is 
consistent with previous findings [4, 6, 11, 18]. Remark-
ably, though, the present study could not demonstrate 
an association between sarcopenia and chronic diseases, 
which may be due to our small sample size and/or selec-
tion bias if the frailest patients with chronic diseases and 
sarcopenia were the ones most likely to decline partici-
pation in the study.
Another aim of the present study was to evaluate if 
the EWGSOP-recommended assessment would be 
super ior to currently used geriatric tests for muscle 
function and muscle strength in identifying geriatric pa-
tients with sarcopenia. Calculating predictive values of 
the chair stand and Timed Up and Go show that these 
tests are not suitable for identifying patients with sarco-
penia.
A larger number of patients were found with path-
ological chair stand and Timed Up and Go results than 
with sarcopenia and/or severe sarcopenia. Common 
conditions among geriatric patients such as balance dis-
turbances, vestibular dysfunction, orthostatic intoler-
ance and fear may interfere with the test results of the 
functional tests, since both the chair stand and Timed 
Up and Go demand a certain degree of standing and 
walking balance. This may result in some pathological 
test findings which are not due to sarcopenia. Con se-
quently, the present findings underline that the chair 
stand and Timed Up and Go may be useful measure-
ments to identify functional limitation and need of phys-
ical training in geriatric patients, but it is important to 
add an assessment of muscle mass (SMI), hand-grip 
strength and gait speed to the comprehensive clinical 
geriatric assessment when aiming to identify sarcopenia.
Effective diagnosis of low muscle mass and parallel 
impairments in muscle function is crucial in order to ini-
tiate early targeted treatments to prevent falls, fractures 
and disability, and ultimately lead to an improved qua l-
ity of life, and it seems important to gain more experi-
ence and knowledge about the various sarcopenia vari-
ables and cutoff values in different populations. 
cOnclUsiOns
Based on the EWGSOP criteria, 26% of the patients in 
the present study had either sarcopenia or severe sarco-
penia. This is in line with previous findings [4, 6, 11, 18]. 
In contrast, there was no association between sarcope-
nia and chronic disease, but high age and poor nutritional 
status were found to be associated with sarcopenia. 
Assessment of sarcopenia using the EWGSOP diag-
nostic method is feasible in a geriatric outpatient popu-
lation as part of the comprehensive geriatric assess-
ment. The currently used geriatric tests for muscle 
function and muscle strength – chair stand and Timed 
Up and Go – cannot identify patients with sarcopenia.
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